Etamsylate - a drug that increases the formation of mucopolysaccharides in the capillary walls and increases the stability of the microvessels.
The drug improves capillary permeability in the condition of the pathological process, and normalizes the microcirculation, has a hemostatic effect. Etamzilat hemostatic effect due to the activation of thromboplastin formation. The drug increases the formation of blood coagulation factor III, improves the adhesion of platelets. Etamsylate no effect on the IPT does not have the properties of hypercoagulation, is not conducive to thrombosis. The high efficiency of the drug provides positive feedback on etamzilat by doctors.
According to the instructions etamzilat, this drug is used for:
- prevent and stop capillary bleeding on the background of diabetic angiopathy;
- surgical interventions in ENT practice (tonsillectomy, microsurgery of the ear, and others);
- ophthalmic surgery (cataract, keratoplasty, protivoglaukomatoznye operations);
- dental surgery (removal of granulomas, cysts, tooth extraction);
- urologic surgery (prostatectomy);
- other surgical, gynecological, including interference, especially in richly vascularised organs and tissues;
- Emergency Action lung, intestinal bleeding;
- hemorrhagic diathesis.
According to the instructions etamzilat, the drug is contraindicated in:
- bleeding due to the use of anticoagulants;
- with extreme caution - if there is thrombosis, embolism in history.
Etamsylate for intramuscular, intravenous, retrobulbar, subconjunctival, oral administration.
The hemostatic effect of the preparation Etamsylate develops after 5-15 minutes after intravenous administration. The maximum effect is achieved in 1-2 hours. Effect of the drug lasts more than 4 hours. The effect of intramuscular application etamzilat develops later. When administered orally, the maximum efficiency is reached in three hours.
From prevention to drug administered intravenously or intramuscularly one hour before surgery, the dosage - 2-4 ml (0, 25-0, 5 g of the active ingredient). It is also possible oral three hours before surgery (2-3 tablets). If necessary Etamsylate can be administered intravenously during surgery. For prevention of postoperative bleeding administered 4-6 ml per day (or 6-8 tablets).
When bleeding therapeutic purposes once the drug is administered 2-4ml and then - at 2ml every four - six hours or 2 tablets. Perhaps etamzilat drip application, this preparation is diluted in conventional infusion solutions. Do not mix this medication with others in the same syringe.
In the treatment of dysfunctional uterine bleeding Etamsylate appoint 0, 5g inside or 0 25 - parenterally administered every six hours, duration of treatment - about 10 days.
In the treatment of hemorrhagic diathesis prescribers courses at a dosage of 1, 5 g per day orally for two weeks. In severe cases, treatment is initiated clinical parenterally (0, 25-0, 5 g twice daily), and then move on to oral.
In diabetic microangiopathy Etamsylate administered in a dosage of 1-2 tablets a day for two to three months.
Dosage for subconjunctival and retrobulbar application - 1ml.
Registered the following side effects when used etamzilat: heaviness in the epigastrium, heartburn, dizziness, headache, flushing of the face, decrease in SBP, allergic reactions, paresthesia of the lower limbs.
Application etamzilat during pregnancy
On the strict application of etamzilat possible during pregnancy, when the expected benefit to the mother's body is much higher potential risk to the fetus. There were no adverse effects on the fetus during pregnancy etamzilat appointment.
Registered analogue etamzilat - Dicynonum.
Reviews etamzilat say enough high efficiency of the drug. Efficiency etamzilat proven in numerous clinical studies.
Before using this drug is recommended to read the instructions to etamzilat.